University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburghon November 15, 2019 at 4:19 pm
For more information, visit www.pieris.com. About the Researchers: Professor Sally Wenzel, MD, is an expert in the asthma field, working with a very strong network of leading scientists and clinicians ...
- Uninfected individuals born to mothers living with HIV at risk of obesity and asthmaon November 15, 2019 at 8:56 am
Adolescents and young adults who were born to mothers with HIV but remained uninfected themselves still face a greatly heightened risk of obesity and asthma-like symptoms ... of the Metabolism Unit, ...
- Broadway star, 13, dies from ‘massive’ asthma attack. What are the warning signs?on November 15, 2019 at 4:00 am
OPHA says Her father Andy Griggs told Page Six his daughter was born with asthma and took medication for the illness throughout her life. “She said, ‘I don’t feel so good,’ which immediately set off ...
- How to Manage Your Child’s Asthma—and What to Do in an Emergencyon November 14, 2019 at 11:32 am
Several factors may go into asthma management for kids, according to the Mayo Clinic, including: Treating inflammation in the airways to prevent asthma attacks with daily medication Treating asthma ...
- Asthma Devices Market – 2019 Industry Share, Size, Statistics, Growth, Opportunity, Trends, Regional Analysis With Global Forecast To 2023on November 14, 2019 at 3:40 am
FindAir focuses on the end-user with emphasizes on the patient experience. FindAir ONE device is a pMDI inhaler add-on attached to asthma medication which collects data for drug usage and information.
- How to Use Your Body’s Pressure Points to Relieve Asthmaon November 14, 2019 at 1:43 am
People living with asthma use a variety of methods to keep their condition under control. Common methods include taking daily medicine to lower inflammation in the airways, and using inhalers for ...
- Broadway Star Laurel Griggs, 13, Tragically Died of an Asthma Attack: Here’s How That Can Happenon November 12, 2019 at 10:56 am
Asthma is the most common chronic illness in children, and attacks can quickly move from manageable to deadly without immediate treatment or effective medication. And sometimes, sadly, people can die ...
- 13-Year-Old Broadway Star Laurel Griggs Dies from Asthma Attack—Here's How That Can Happenon November 11, 2019 at 4:01 pm
While there’s no cure for asthma, there are ways to control it, most effectively by taking medication—either via an inhaler or in pill form. An asthma attack can occur when an individual is exposed to ...
- Asthma can turn deadly in rare caseson November 11, 2019 at 12:32 pm
There are two types of medicine: quick relief and long-term control. "Quick-relief medicines control the symptoms of an asthma attack. If you need to use your quick-relief medicines more and more, you ...
- Young Broadway star’s death reveals asthma’s fatal consequenceson November 11, 2019 at 10:06 am
This leads to difficulty breathing, wheezing, coughing and shortness of breath, according to WebMD.com. If a person doesn’t get an immediate dose of their asthma medication, which usually consists of ...
via Bing News